Twitter Facebook LinkedIn YouTube

New Listing: InnoCan Pharma Corporation (CSE:INNO)

Video Platform Video Management Video Solutions Video Player

The company is a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations.

Additional Information:

Company: InnoCan Pharma Corporation
Website: http://www.InnocanPharma.com
Stock Symbol: CSE: INNO
Date Published: Sep 27, 2019
Transcript: Available

Video Transcript:

I’m Cassandra Bolinski for Investmentpitch Media

InnoCan Pharma Corporation is one of the latest new listings on the Canadian Securities Exchange, trading under the symbol “INNO”, followings its initial public offering.

The company raised gross proceeds of $1.1 million from the sale of approximately 6.1 million units priced at $0.18 per unit.

Each unit consisted of 1 share and one-half a warrant with each full warrant exercisable at $0.30 for 24 months, subject to an acceleration clause.

Leede Jones Gable acted as agent for the offering.

The company is a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations.

Iris Bincovich, CEO, stated: “We are delighted to begin trading on the CSE, the world’s preeminent public exchange for innovative CBD based product companies. InnoCan has diligently and methodically developed a unique portfolio of CBD products that we expect to bring to various markets in the near term.”

The company’s business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products; (ii) research and development of non-pharmaceutical products for third parties in exchange for fees and/or royalties; and (iii) research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales.

InnoCan Israel has begun the development of a number of products for the relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain.

The company anticipates launching its CBD integrated pharmaceuticals into the U.S. market by the first quarter of 2020.

The shares are trading at $0.25.

For more information, please visit the company’s website www.InnocanPharma.com, contact
Iris Bincovich, Founder & CEO, +972.54.301.2842 or by email at IrisB@InnocanPharma.com.

For investor relations, please contact Andreas Curkovic of Proconsul Capital, who can be reached at 416-577-9927.

I’m Cassandra Bolinski for Investmentpitch Media